Search Here

Researchers at Purdue University have made groundbreaking strides in developing a novel treatment for glioblastoma brain tumors, a condition deemed incurable with conventional therapies.

Treating 'Incurable' Brain Tumors

This pioneering approach to something previously considered 'incurable' offers hope for patients facing this deadly disease.

Led by Sandro Matosevic, an associate professor at Purdue's College of Pharmacy, the research team has engineered fully off-the-shelf natural killer cells derived from stem cells to combat glioblastoma. Unlike traditional therapies, which often prove ineffective against this aggressive form of cancer, this innovative immunotherapy targets the tumors directly.

Eliminating Limitations of Traditional Therapies

Traditional cell therapies have primarily relied on autologous cells, sourced from and returned to the same patient. However, these approaches have shown limited efficacy against glioblastoma. In contrast, Purdue's immunotherapy utilizes genetically engineered allogeneic immune cells derived from induced pluripotent stem cells, eliminating the need for patient-specific blood cells.

Promising Preclinical Results

The efficacy of Purdue's treatment has been validated through preclinical studies involving animal models. Direct injection of engineered immune cells into mice bearing human brain tumors demonstrated remarkable tumor-targeting capabilities, resulting in complete tumor elimination. These findings signify a significant breakthrough in glioblastoma treatment.

Towards Clinical Translation

With promising preclinical results, the next crucial step involves conducting clinical trials to evaluate the therapy's effectiveness in human patients with brain tumors. Matosevic and the research team are actively working towards this goal, collaborating with neurosurgical clinicians to secure funding and initiate clinical protocols.

Protecting Intellectual Property and Securing Support

Recognizing the innovation's potential, Purdue has taken steps to protect the intellectual property associated with the glioblastoma treatment. The Purdue Innovates Office of Technology Commercialization has filed for a patent to safeguard the therapy's development. Additionally, the research team has received funding from various organizations, including the National Institutes of Health and industry partners.

Ongoing Transformative Efforts

Purdue University's breakthrough in glioblastoma therapy offers a ray of hope for patients facing this devastating disease. By harnessing the power of stem cell-derived natural killer cells, researchers are paving the way for a transformative approach to treating brain tumors. With ongoing efforts to advance the therapy into clinical trials, Purdue remains committed to bringing effective and accessible treatment options to those in need.